Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AG-946 in Healthy Volunteers and Sickle Cell Disease
NCT04536792Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of tebapivat in sickle cell disease (SCD) (5 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Number of Participants Who Experienced at Least One Adverse Event (AE), Number of Participants Who Experienced at Least One Serious Adverse Event (SAE) and 1 more. Started Jul 2020; status: completed.
02
Drugs
tebapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04536792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04536792.